From 1st March 2020, the Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative. This will allow people with type 1 diabetes under the age of 21 and those over the age of 21 who have valid concessional status to access fully subsidised CGM devices through the National Diabetes Services Scheme (NDSS).
A summary of the new access from the 1st of March 2020 is:
The eligibility criteria for each group is available on the NDSS. Talk to your healthcare professional to further discuss the eligibility criteria.
Find more information about continuous glucose monitoring here.
By using a CGM platform, such as Dexcom G5 Mobile or Dexcom G4 PLATINUM studies indicate significantly improved HbA1c1 and lessened risk of hypoglycaemia. 1,2
Both platforms transmit data to display a dynamic trend line which can indicate glucose direction and rate of change. By using CGM, one can proactively manage glucose levels and can treat before hypoglycaemia.
Always read the label and use only as directed. Read the warnings available on https://www.amsldiabetes.com.au/resources before purchasing. Consult your healthcare professional to see which product is right for you.
1. Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538. doi:10.1089/dia.2016.0171 2. Welsh J, Gao P, Derdzinski M et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther. 2019;21(3):128-132. doi:10.1089/dia.2018.0374
Dexcom, Dexcom G5, Dexcom G4, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.
Now you can get all the latest news and updates of our products, events and resources right into your inbox.
We are always happy to help, send us a message or enquiry